Wells Fargo analyst Nathan Treybeck resumed coverage of iRhythm (IRTC) with an Equal Weight rating and $86 price target The analyst believes stock upside will be limited until there is greater certainty on resolving outstanding regulatory issues. Until there is a clean facility re-inspection and the current 483s and warning letter are lifted, there continues to be risk of additional 483s or the current 483s becoming another warning letter or a potential consent decree, the analyst tells investors in a research note.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm presents five new studies on long-term continous monitoring
- iRhythm Technologies Updates Equity Incentive Plan
- iRhythm price target lowered to $79 from $100 at Baird
- iRhythm Technologies Faces Potential Stockholder Dilution and Market Pressure from 2029 Notes Conversion
- iRhythm price target lowered to $125 from $137 at Canaccord